Idecabtagene Vicleucel: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and HAS (France) recommended or restricted idecabtagene vicleucel, while ZIN (Netherlands) did not recommend it.
The record spans 4.4 years, opening at HAS (France) on 15 Dec 2021 and running to 21 May 2026.
No assessment is on file from PBAC (Australia), SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for idecabtagene vicleucel, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 14 of 16 records date from 2023 or later.
HAS (France) was first to assess idecabtagene vicleucel, on 15 Dec 2021; AOTMIT (Poland) did not open a file until 31 Jul 2025 — a wide spread of 3.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
4 of the 9 agencies here assessed idecabtagene vicleucel more than once, CIPM (Spain) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for idecabtagene vicleucel.
The full ledger for idecabtagene vicleucel reads 6 recommended, 4 not recommended, 2 terminated and 1 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 31 Jul 2025 | programu lekowego B.54 Leczenie chorych na szpiczaka plazmocytowego (ICD-10: C90.0) Prezes Agencji rekomenduje objęcie r… | recommended conditionally | source |
| NICE (England) | 23 Jul 2025 | NICE TA1084 | terminated appraisal | source |
| CIPM (Spain) | 21 May 2025 | SECRETARIA DE ESTADO DE SANIDAD 27 MINISTERIO DE SANIDAD Indicaciones terapéuticas autorizadas: Abecma está indicado en … | not financed by the SNS · art. 92 d, e | source |
| ZIN (Netherlands) | 19 May 2025 | Advies - niet vergoeden idecabtagene vicleucel (Abecma®) voor de behandeling van multipel myeloom | not reimbursed | source |
| NYE METODER (Norway) | 22 Sep 2024 | Behandling av voksne pasienter med tilbakevendende og refraktær myelomatose som har fått minst tre tidligere behandlinge… | decision recorded | source |
11 further decisions for idecabtagene vicleucel, across 6 agencies, are not shown here. They include the most recent record on file, 21 May 2026 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- pirtobrutinib — same ATC class L01 — Antineoplastics
- ripretinib — same ATC class L01 — Antineoplastics
- cabotegravir — also decided by AIFA in 2026Q2
- vutrisiran — also decided by AIFA in 2026Q2
- vamorolone — also decided by AIFA in 2026Q2
- ciltacabtagene autoleucel — also decided by AIFA in 2026Q2
Coverage: 16 decisions for idecabtagene vicleucel from 9 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01 — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.